Texas has committed $50 million to study ibogaine as a treatment for veterans and first responders struggling with PTSD and addiction — the largest state-funded psychedelic research initiative in U.S. history. Governor Greg Abbott signed the bill into law in June 2025 C.E., authorizing the Texas Health and Human Services Commission to fund clinical trials of the powerful plant-derived compound. The move marks a striking moment in American public health: a politically conservative state stepping ahead of the federal government to confront a crisis that conventional medicine has failed to solve.
At a glance
- Ibogaine research funding: Texas approved $50 million for supervised clinical trials, surpassing any previous state or federal public investment in psychedelic medicine research.
- Target populations: The program prioritizes military veterans and first responders, groups with high rates of treatment-resistant PTSD and opioid use disorder.
- Ibogaine origin: The compound comes from the root bark of Tabernanthe iboga, a shrub native to Central Africa, where it has been used in Bwiti spiritual traditions for centuries — a history that mainstream research rarely acknowledges.
Why ibogaine is getting serious attention
Ibogaine sits in a strange position in American medicine: federally classified as a Schedule I substance with no accepted medical use, yet supported by a growing body of peer-reviewed evidence suggesting it can interrupt opioid dependence after a single treatment session.
A landmark study published in Nature Medicine in 2023 C.E., led by researchers at Stanford University School of Medicine, found that a single ibogaine dose — administered under medical supervision in Mexico, where it is legal — dramatically reduced PTSD, depression, and alcohol use in U.S. Special Operations veterans. Disability ratings dropped by an average of 88 percent at one-month follow-up. No existing FDA-approved drug comes close to those numbers for this population.
The federal scheduling barrier has made it nearly impossible to conduct the large, controlled trials needed to translate that promise into clinical practice. Texas is now betting $50 million that state funding can cut through that bottleneck.
What the money will actually do
The Texas Health and Human Services Commission will oversee the distribution of funds to research institutions running supervised clinical trials. The goal is to generate the safety and efficacy data required for eventual FDA approval — a pathway that requires exactly the kind of rigorous, multi-site trial this funding is designed to support.
Organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) have spent decades building the regulatory and scientific infrastructure for psychedelic medicine research. Texas’s investment effectively plugs into that framework at a scale no state has attempted before.
For veterans in particular, the stakes are high. The U.S. Department of Veterans Affairs estimates that approximately 17 veterans die by suicide every day. Conventional PTSD treatments — therapy, antidepressants, mood stabilizers — fail a significant portion of those who try them. Ibogaine’s mechanism, which appears to reset certain neural pathways rather than simply managing symptoms, offers a fundamentally different approach.
The deeper roots of this compound
It is worth placing ibogaine in its full cultural context. The Bwiti people of Gabon and Cameroon have used iboga in initiation and healing ceremonies for generations. Western researchers first isolated ibogaine in the early 20th century C.E., and American addiction researchers began studying it seriously in the 1960s C.E. — before federal drug scheduling effectively shut that work down.
Some Indigenous and African scholars have raised questions about how the global psychedelic medicine industry engages with the plant’s origins, including issues of benefit-sharing and intellectual attribution. As Texas’s program moves forward, how it acknowledges and potentially compensates those knowledge traditions will matter — though the legislation does not address this directly.
A signal beyond Texas
The bipartisan nature of this legislation is itself significant. Texas is not a state typically associated with progressive drug policy. That this bill passed with strong support across party lines — driven largely by veterans’ advocacy groups — suggests that ibogaine research has found a political coalition that other psychedelic therapies have not yet managed to build.
Researchers at institutions including Stanford Medicine and the Johns Hopkins Center for Psychedelic and Consciousness Research have been among the most vocal advocates for removing research barriers. Texas’s move may accelerate federal reconsideration of ibogaine’s scheduling status — a conversation that has already begun quietly within the FDA’s Breakthrough Therapy program.
There is still much that clinical trials will need to resolve. Ibogaine carries real cardiac risks — it can prolong the QT interval, a measure of heart rhythm — and safe administration requires medical screening and monitoring that are not yet standardized. The Texas program’s success will depend heavily on how rigorously those safety protocols are designed and enforced.
But the commitment itself — $50 million, clinical-grade, state-backed — moves ibogaine research from the margins to the mainstream in a way that few developments in recent years have matched. For the veterans and first responders it aims to serve, that shift cannot come fast enough.
Read more
For more on this story, see: Good News for Humankind — Texas ibogaine bill
For more from Good News for Humankind, see:
- Ghana creates a new marine protected area at Cape Three Points
- Indigenous land rights get a major boost ahead of COP30
- The Good News for Humankind archive on health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana creates its first marine protected area to rescue depleted fish stocks
Ghana has declared its first marine protected area near Cape Three Points on the Gulf of Guinea, marking a historic step to reverse decades of overfishing. The protected zone aims to restore fish populations that have collapsed under pressure from industrial trawling and illegal fishing. The decision supports 2.7 million Ghanaians whose livelihoods depend on healthy coastal fisheries and aligns Ghana with the global goal of protecting 30 percent of the world’s oceans by 2030.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
For the first time, researchers have evidence that removing amyloid plaques from the brain before symptoms appear can cut Alzheimer’s risk by roughly half. A clinical trial published in The Lancet Neurology, led by Washington University School of Medicine in St. Louis, found that long-term treatment with the antibody drug gantenerumab significantly delayed dementia onset in people with a rare genetic form of the disease. The findings provide the clearest signal yet that intervening years before symptoms emerge can change the course of Alzheimer’s disease.
